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Abstract 
Indomethacin, a potent nonsteroidal anti-inflammatory drug, has been used in 
the treatment of various kinds of pains, inflammation and arthritis. However, oral 
administration of indomethacin produces serious gastrointestinal adverse 
effects. Therefore the aim of the present investigation was to evaluate the anti-
inflammatory effects, skin irritation, activation energy and histopathology of 
indomethacin from transdermally applied true nanoemulsion. The anti-
inflammatory effects of true nanoemulsions were compared with marketed 
Indobene
® gel on carrageenan-induced paw edema in rats. Skin irritation tests 
were performed on Wistar rats for 14 days. The % inhibition value after 12 h 
application was significant for optimized formulation F6 (83) as compared to 
marketed Indobene
® gel (P<0.01). Results of skin irritation test indicated that 
developed true nanoemulsion is safe for human use. The significant decrease in 
activation energy (1.396 kcal/mol) for indomethacin across rat skin indicated 
that the stratum corneum lipid bilayers were significantly disrupted (P<0.05). 
From these results it was concluded that the developed nanoemulsion have 
great potential for transdermal application of indomethacin. 
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Introduction 
Indomethacin, a potent nonsteroidal anti-inflammatory drug (NSAID) has been used in the 
treatment of various kinds of pains, inflammation and arthritis [1,  2]. However oral 
administration of indomethacin produces serious gastrointestinal (GI) adverse effects upon 
chronic administration [2]. Therefore an alternative route is required to eliminate these oral 
adverse effects. Transdermal route has been known to eliminate oral GI adverse effects 
and maintains the plasma drug level for longer period of time and suitable for long 
treatment of chronic diseases like arthritis [3–8]. Therefore the aim of the present study 
was to evaluate the anti-inflammatory effects, skin irritation and skin permeation 
mechanism of indomethacin from transdermally applied true nanoemulsion in order to 
eliminate its GI adverse effects.  
True nanoemulsions and oil-in-water (o/w) nanoemulsions are same systems and they are 
thermodynamically stable transparent isotropic dispersions of oil and water stabilized by 
an interfacial film of surfactant molecules having the droplet size less than100 nm [8–10]. 
These systems are different from lipid nanoemulsions in terms of thermodynamic stability 
[10]. True nanoemulsions or nanoemulsions have been known to increase skin 
permeation, therapeutic efficacy and bioavailability of many drugs [4–15]. True nano-
emulsions have been proved good vehicle for enhancement of anti-inflammatory effects 
(therapeutic efficacy) of some anti-inflammatory drugs [4,  7,  11]. Skin permeation 
mechanism of some anti-inflammatory drugs like celecoxib and aceclofenac using different 
techniques like fourier transform infra-red (FTIR), differential scanning calorimetry (DSC), 
activation energy determination and histopathological examination using true 
nanoemulsion has also been reported [7, 9]. Development, characterization and ex vivo 
skin permeation studies of indomethacin loaded true nanoemulsions have already been 
discussed in our previously published article [10]. Anti-inflammatory effects, skin irritation 
and skin permeation mechanism of indomethacin using true nanoemulsion have not been 
discussed in our previous article [10]. Moreover this in vivo evaluation (anti-inflammatory 
effects, skin irritation and skin permeation mechanism) has not been reported in the 
literature. Therefore in this article we evaluate the anti-inflammatory effects, skin irritation 
and skin permeation mechanism of indomethacin from transdermally applied nano-
emulsion and compare its therapeutic effects with marketed Indobene
®  gel. Nano-
emulsions were prepared using nonirritant, pharmaceutically acceptable ingredients 
without using additional chemical enhancers.  
Results and discussion 
True nanoemulsions of indomethacin were successfully prepared and characterized in 
terms of droplet size, viscosity, refractive index and in vitro skin permeation profile [10]. 
Based on the best skin permeation profile, lowest droplet size (25.53 & 34.64 nm for F6 
and F7 respectively) and lowest viscosity (14.32 and 21.53 cp for F6 & F7 respectively), 
formulations F6 and F7 were selected for in vivo studies [10]. Anti-inflammatory effects of 
indomethacin in optimized formulations (F6 and F7) were evaluated to prove their 
therapeutic efficacy. Anti-inflammatory effects of developed nanoemulsions were also 
compared with marketed Indobene
® gel. The results of these studies are given in Table 1 
and Figure 1. The % inhibition value after 12 h application was found to be highest for F6 
(83) as compared to marketed Indobene
® gel (32.1 %). This difference was extremely 
significant at 1 % level of significance (P<0.01) (Figure 1). The % inhibition value was  Preparation  and  In Vivo Evaluation of Indomethacin Loaded True Nanoemulsions   49 
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intermediate for formulation F7 (69.7). Initially (after 1, 2 and 3 h) % inhibition value was 
very low for both nanoemulsions. After 6 and 12 h there was significant enhancement in 
this value which indicated the sustained type of anti-inflammatory effects in formulations 
F6 and F7 (P<0.05). The anti-inflammatory effects of marketed Indobene
® gel were very 
poor after 1, 2, 3, 6 and 12 h application which indicated that marketed gel can be used 
only for topical or local drug delivery. On the other hand results of nanoemulsion 
formulations indicated that it can be used for local as well as for transdermal drug 
(systemic) delivery system (Figure 1 and Table 1). An increase in systemic anti-
inflammatory effects of indomethacin leads to complete inhibition of the inflammation 
process [11]. Local gradient coupled with the increase in the amount of indomethacin that 
is absorbed over the period of 12 h caused almost complete inhibition of inflammation by 
nanoemulsion formulation.  
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Fig. 1.   Anti-inflammatory effects of true nanoemulsion (F6), true nanoemulsion (F7) 
and marketed Indobene
® gel in Wistar male rats 
The enhanced anti-inflammatory effects of true nanoemulsions could be due to the 
enhanced permeation of indomethacin through the skin [10]. 
Although all the materials used for preparation of nanoemulsion were falled under 
generally regarded as safe (GRAS) category. Concentration of all materials is very critical 
issue for these formulations. Large amount of surfactants is usually irritant to the skin. 
Therefore skin irritation tests were performed to confirm concentration of materials used 
for nanoemulsion preparation is safe. Moreover concentrations that we used in our 
formulations is beyond the limit that given in USFDA. Therefore these studies were 
necessary to confirm safety of developed formulation. Therefore skin irritation test was 50 F.  Shakeel  et al.:  
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performed to confirm the safety of optimized true nanoemulsions of indomethacin. 
Van-Abbe et al. (1975) mentioned that a value between 0 and 9 indicates that the applied 
formulation is generally not irritant to human skin [16].  
Tab. 1.   Anti-inflammatory effects of F6, F7 and Indobene
® gel in carrageenan-induced 
rat paw edema 
Group Formulation N  Mean  Wt± 
SD (g) 
Time 
(h) 
Mean % 
Edema ± SD 
% 
inhibition 
I Control 
(carrageenan 
only) 
6 210.0±22.5 1 
2 
3 
6 
12 
27.2±3.1 
40.0±4.1 
74.5±5.7 
57.0±4.2 
38.3±3.3 
 
II F6  6  220±25.5  1 
2 
3 
6 
12 
24.6±2.4 
33.4±2.8 
47.3±4.1 
14.0±1.8 
6.5±1.2 
9.5 
16.5 
36.5 
75.4 
83.0 
III F7  6  240.0±32.0 1 
2 
3 
6 
12 
25.5±2.9 
34.7±3.2 
49.5±4.8 
20.0±2.9 
11.6±1.4 
6.2 
13.2 
33.5 
64.9 
69.7 
IV Indobene
® 
gel 
6 245.0±35.5 1 
2 
3 
6 
12 
26.4±3.7 
37.8±4.9 
59.3±5.7 
42.0±4.5 
26.0±2.6 
2.9 
5.5 
20.4 
26.3 
32.1 
N = Number of rats in each group; SD = Standard deviation 
 
The mean values of skin irritation score for formulation F6 and F7 were found to be 1.66 ± 
1.03 and 2.50 ± 0.54 respectively. From these results of 14 days test it was concluded that 
formulations F6 and F7 were safe to be used as transdermal drug delivery system 
(Table 2).  
Tab. 2.   Skin irritation score of the true nanoemulsions F6 and F7 
Score after (days)  S.No  Group 
1  2  3  4  7  14 
Mean score± SD 
1  I (F6)  2  0  3  2  1  2  1.66± 1.03 
2  II (F7)  3  2  2  3  3  2  2.50± 0.54 
 
The value of activation energy (Ea) could modify due to changes in skin composition and 
hence change the physicochemical properties of drug [7–9]. Nanoemulsions because of 
their action on stratum corneum (SC) lipids can change the value of Ea. The Arrhenius plot  Preparation  and  In Vivo Evaluation of Indomethacin Loaded True Nanoemulsions   51 
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between logarithms of permeability coefficient (log Pb) and reciprocal of absolute 
temperature (1/T) was found linear in the temperature range of 27–47°C as shown in 
Figure 2, indicating no significant structural or phase transition changes within the skin 
membrane. The Ea value for permeation of indomethacin across rat skin was determined 
from the slope of Arrhenius plot (Figure 2). The Ea of indomethacin from true 
nanoemulsion F6 was found to be 1.396 kcal/mol. The activation energy for ion transport 
has been reported as 10.7 and 4.1 kcal/mol across phosphatidylcholine bilayer and human 
epidermis respectively [17,  18]. The significant decrease in Ea value for indomethacin 
permeation across rat skin indicated that the SC lipid bilayers were significantly disrupted 
(P<0.05). 
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Fig. 2.   Arrhenius plot of true nanoemulsion F6 for determination of activation energy 
through rat skin 
In our study, Ea of indomethacin from formulation F6 was 1.396 kcal/mol. Therefore it was 
interpreted that nanoemulsions create pathways in the lipid bilayers of SC resulting in 
enhanced transdermal permeation of indomethacin [19]. 
Histopathological examination of nanoemulsion treated and control rat skin was performed 
using Carl Zeiss light microscope. The photomicrographs of control rat skin showed 
normal skin layers as shown in Figure 3A. When the skin was treated with nanoemulsion 
(F6) for 24 h, definite changes were observed in the skin morphology as shown in Figure 
3B that could be due to the action of true nanoemulsion on stratum corneum. Dermis does 
not show any inflammatory cell infiltration (Figure 3B). There were no apparent signs of 
skin irritation (erythma and edema) observed on skin specimens treated with nano-
emulsion F6 indicating the absence of any skin irritation as a consequence of true 
nanoemulsion treatment. These results indicated that developed nanoemulsion is safe for 
transdermal delivery of indomethacin. 
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Conclusion 
The in vivo anti-inflammatory studies revealed significant increase in % inhibition value of 
F6 as compared to marketed Indobene
® gel (P<0.05). This indicates that developed 
nanoemulsion formulation is efficacious. Results of skin irritation test indicated that 
formulation F6 is safe for human use. The significant decrease in activation energy for 
indomethacin indicates that the SC lipid bilayers was significantly disrupted (P<0.05). From 
these results it can be concluded that the developed nanoemulsion have great potential for 
transdermal application of indomethacin. 
   
(A) (B) 
Fig. 3.   Photomicrograph of skin sample from (A) control group animal and (B) true 
nanoemulsion (F6) treated animal at low power (40 X) 
Experimental 
Materials  
Indomethacin was purchased from SAMA Impex (Berlin, Germany). Oleoyl macroglyceride 
(labrafil M1944CS) and diglycol monoethyl ether (transcutol-HP) were kind gift samples 
from Gattefossé (Cedex, France). Tween-80 was purchased from Sigma Aldrich (St. Louis, 
MO, USA). Marketed indomethacin gel (Indobene
®) was purchased from local market 
(Benghazi, Libya). All other chemicals used were of analytical reagent (AR) grade. 
Preparation of true nanoemulsions  
Various true nanoemulsions of indomethacin were prepared by spontaneous emulsification 
method (aqueous phase titration method). Two optimized nanoemulsion (F6 and F7) were 
selected for in vivo studies [10]. Selection of these optimized formulations was based on 
the best in vitro skin permeation profile, lowest viscosity, least polydispersity index, lowest 
droplet size and optimum surfactant concentration [10]. These true nanoemulsions were 
prepared by dissolving 0.5 % w/w of indomethacin in specified quantity of cosurfactant 
(transcutol-HP). Then surfactant (Tween-80) and oil (labrafil M1944CS) were added slowly 
in the oil phase. Then sufficient quantity of distilled water was added to get the final 
preparation 100 % w/w. The composition of these true nanoemulsions is given in Table 3.  
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Tab. 3.   Compositions of true nanoemulsion F6 and F7 
Ingredients (% w/w) F6  F7 
Indomethacin 0.5  0.5 
Labrafil M1944CS  5.0  10.0 
Tween-80   33.75  45.0 
Transcutol-HP 11.25  15.0 
Distilled water (q.s.)  100.0  100.0 
q.s. = Quantity sufficient to produce total 
formulation 100 % w/w 
 
In vivo anti-inflammatory effects 
Approval to carry out in vivo anti-inflammatory studies was obtained from the Local Animal 
Ethics Committee, Al-Arab Medical University, Benghazi, Libya and their guidelines were 
followed for the studies. The sustained anti-inflammatory effects of the optimized formu-
lations (F6 and F7) were evaluated by carrageenan-induced hind paw edema method 
developed in Wistar rats by Winter et al. 1965 [20]. Young male Wistar rats weighing 200–
250 g were randomly divided into 4 groups: control, true nanoemulsion (F6), true 
nanoemulsion (F7) and marketed indometacin (Indobene
®) gel each containing 6 rats. The 
animals were kept under standard laboratory conditions, at a temperature of 25 ± 1°C and 
relative humidity of 55 ± 5%. The animals were housed in polypropylene cages, with free 
access to standard laboratory diet (Lipton feed, Tripoli, Libya) and water ad libitum. Dose 
for the rats was calculated based on the weight of the rats according to the surface area 
ratio [7, 8]. The dorsal side of the rats was shaved 12 h before starting the experiments 
except in control group. Formulations F6, F7 and Indobene
® gel were applied on the 
shaved dorsal region of all animals (except in control group) half an hour before subplanter 
injection of carrageenan in right paw. Paw edema was induced by injecting 0.1 ml of 1 % 
w/v dispersion of carrageenan in distilled water. The volume of paw was measured at 1, 2, 
3, 6, and 12 h after injection using digital plethysmometer (Ugo Basile, Italy). 
The amount of paw swelling was determined time to time and expressed as percent 
edema. Percent inhibition of edema produced by each formulation-treated group was 
calculated against the respective control group. 
Results of these studies were compared using Dunnett test of one-way analysis of 
variance (ANOVA). 
Skin irritation test 
Skin irritation test was performed on developed formulations F6 and F7 on male Wistar 
rats weighing 200–250 g. Wistar rats were divided into 2 groups: true nanoemulsion (F6) 
and true nanoemulsion (F7) each contain 6 rats. The animals were kept under standard 
laboratory conditions, temperature at 25 ± 1°C and relative humidity (55 ± 5%). The 
animals were housed in polypropylene cages, six per cage, with free access to standard 
laboratory diet (Lipton feed, Tripoli, Libya) and water ad libitum. A single dose of 10 µl of 
each optimized nanoemulsion formulation (F6 and F7) was applied to the left ear of the rat 
with the right ear as a control. The development of erythema was monitored for 14 days 
using the reported method of Van-Abbe et al. [16].  54 F.  Shakeel  et al.:  
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Determination of activation energy 
For determination of activation energy of indomethacin, in vitro skin permeation studies 
across rat skin were carried out at 27, 37 and 47°C in the vehicle methanolic phosphate 
buffer saline (PBS pH 7.4) (1:9) [7–9]. In the donor compartment, 1 ml of formulation was 
taken (containing 5 mg of indomethacin). Receiver compartment was composed of the 
vehicle methanolic PBS only. Permeability coefficients were determined at each 
temperature and activation energy of indomethacin was then calculated from Arrhenius 
equation [7–9].  
P = Po e
−Ea/RT  
Where Ea is the activation energy, R is gas constant (1.987 kcal/mol), T is absolute 
temperature (K), P is the permeability coefficient and Po is the Arrhenius factor. 
Histopathological examination of skin specimens 
Dorsal skin of Wistar rat was treated with optimized true nanoemulsion (F6) in methanolic 
PBS pH 7.4. After 24 h, rat was sacrificed and the skin samples from treated and 
untreated (control) area were taken. Each skin sample was stored in 10 % formalin 
solution in methanolic PBS (pH 7.4). The skin samples were cut into vertically in different 
sections. Each section was dehydrated using ethanol, embedded in paraffin for fixing and 
stained with xylene. Skin samples were then observed under light microscope (Axioskop 
40 FL, Carl Zeiss, Germany)) fitted with canon power shot G3 digital camera and 
compared with control sample. The light microscopy was performed at low magnification 
level (40X) [21, 22].  
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